JAK Inhibitors for Alopecia Areata vs Natural Options

Three oral JAK inhibitors are FDA-approved for severe alopecia areata: baricitinib (Olumiant, 2022), ritlecitinib (Litfulo, 2023) and deuruxolitinib (Leqselvi, 2024). They are the first treatments that reliably regrow hair in a meaningful share of people with extensive disease. Natural approaches have a role in supporting health, but no supplement has shown comparable regrowth. This article compares the drugs, covers their safety limits and shows where natural measures fit. For the natural side in full detail, see natural remedies for alopecia and alopecia areata supplements.

The Three Approved Drugs

"Severe" generally means substantial scalp hair loss (often 50% or more). Insurance coverage typically follows this definition.

How Well Do They Work?

Trial endpoints used the SALT score, where 20 or below means 20% or less of scalp hair missing. Results at the trial endpoint:

• Baricitinib 4 mg: 38.8% (BRAVE-AA1) and 35.9% (BRAVE-AA2) reached SALT 20 or below at week 36, against 6.2% and 3.3% on placebo. The 2 mg dose worked in fewer people (22.8% and 19.4%). In adolescents aged 12 to under 18, 42% on 4 mg reached SALT 20 or below at week 36 against 5% on placebo (BRAVE-AA-PEDS, Lilly press release).
• Ritlecitinib 50 mg: 23% reached SALT 20 or below at week 24, against 2% on placebo (ALLEGRO-2b/3), with more reaching it over longer treatment.
• Deuruxolitinib: in THRIVE-AA1, 29.6% on 8 mg and 41.5% on 12 mg twice daily reached SALT 20 or below at week 24, against 0.8% on placebo. THRIVE-AA2 reported broadly similar results.

Cross-trial comparison is unreliable because populations, timepoints and severity differ. A head-to-head trial is the only fair comparison.

Evidence grade for regrowth: A (multiple placebo-controlled phase 3 trials).

What Happens When You Stop?

JAK inhibitors suppress the pathway rather than remove the cause. In clinical experience and extension studies, regrowth commonly recedes after stopping, so many people stay on treatment long term while it works and is tolerated. Earlier treatment, within a year or so of onset, has been linked to better response in the adolescent baricitinib programme.

Safety: The Boxed Warning and Monitoring

All three drugs carry the class boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events (MACE) and thrombosis. The warning originates from a tofacitinib study in people with rheumatoid arthritis aged 50 or older with cardiovascular risk factors. Many people with alopecia areata are younger and healthier, but the label applies to the class and your prescriber must weigh your personal risk (smoking, clot history, age, heart disease).

Typical practical issues include:

• Infection screening: tuberculosis and hepatitis checks before starting are standard for JAK inhibitors, and live vaccines are generally avoided during treatment.
• Blood tests: blood counts, liver enzymes and lipids are monitored.
• Common side effects: acne, upper respiratory infections and headache are widely reported.
• Deuruxolitinib specifics: the label contraindicates use in CYP2C9 poor metabolizers and with moderate or strong CYP2C9 inhibitors, and advises avoiding strong CYP3A4 inducers and combining it with other JAK inhibitors, biologics or potent immunosuppressants.

Where Natural Approaches Fit

Honest framing: no diet or supplement has shown JAK-level regrowth. The strongest natural-evidence items are modest, and the best-studied basics are correcting deficiencies. For example, zinc and vitamin D have limited data in alopecia areata, and we grade them below the drug trials. See the full comparison below.

Reasonable roles for natural measures alongside a JAK inhibitor, if your dermatologist agrees:

• Correct documented deficiencies (vitamin D, iron, zinc) found on blood tests.
• Anti-inflammatory eating, which supports general health. See alopecia areata diet.
• Stress and sleep support, since flares are commonly linked to stress, though the causal evidence is limited.
• If you also have Hashimoto's, treat the thyroid too. See Hashimoto's hair loss.

Supplements to be careful with: immune-stimulating herbs and products ("immune boosters"), and St John's wort, a well-known CYP3A4 inducer that could interfere with some JAK inhibitors. Check every supplement with your prescriber or pharmacist. For a broader view of what to avoid in autoimmune disease, see best supplements for autoimmune disease.

Preparing for the Dermatology Conversation

• How severe is my disease by SALT score, and does it qualify for a JAK inhibitor under my insurance?
• Which drug suits my age, other conditions and medicines?
• What screening and blood tests are needed before and during treatment?
• What happens if I stop, and what is the plan if it does not work?
• Which supplements are safe with my treatment?

Take the free 3-minute AutoimmuneFinder quiz for a personalized, evidence-graded protocol to discuss with your care team.

Frequently Asked Questions

Which JAK inhibitors are FDA-approved for alopecia areata?

Baricitinib (Olumiant), ritlecitinib (Litfulo) and deuruxolitinib (Leqselvi), all for severe disease. Approval ages differ, so confirm the current label for your age.

Do JAK inhibitors cure alopecia areata?

No. They suppress the immune pathway, and regrowth often fades after stopping.

Do JAK inhibitors have a boxed warning?

Yes, all three carry the class boxed warning for serious infections, mortality, malignancy, MACE and thrombosis.

Can I take supplements while on a JAK inhibitor?

Correcting a documented deficiency is generally reasonable, but check each product with your prescriber. Avoid immune-stimulating products and St John's wort unless cleared.

This site provides educational information only. Not medical advice. Always consult your healthcare provider before changing your treatment plan.